Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract

Core Insights - Paratek Pharmaceuticals announced positive top-line results from two animal studies supporting the development of NUZYRA for the treatment of pulmonary anthrax [1][3] - The studies involved a non-human primate model and a rabbit model, with the latter's data to be presented in Spring 2026 [1][3] - The positive findings have led to additional procurement of NUZYRA under the Project BioShield contract with BARDA [2][6] Group 1: Study Results - The NHP study data were previously presented at a conference, while pivotal rabbit study data will be shared at an upcoming conference [1] - These studies confirm NUZYRA's therapeutic efficacy in treating pulmonary anthrax, building on previous findings for post-exposure prophylaxis [3] Group 2: Contract and Procurement - The BARDA contract, valued at approximately $304 million, supports the development of NUZYRA and includes procurement of up to 10,000 treatment courses for anthrax [6] - Oral NUZYRA tablets associated with this procurement were produced in the U.S. as part of the company's onshoring initiative [2][6] Group 3: Company Overview - Paratek Pharmaceuticals focuses on developing specialty therapies for public health threats and unmet medical needs, with products including NUZYRA and XHANCE [5] - The company is privately held by B-FLEXION Life Sciences [5]